From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
Challenges and new technologies in adoptive cell therapy
P Zhang, G Zhang, X Wan - Journal of Hematology & Oncology, 2023 - Springer
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
Charge-altering releasable transporters enhance mRNA delivery in vitro and exhibit in vivo tropism
The introduction of more effective and selective mRNA delivery systems is required for the
advancement of many emerging biomedical technologies including the development of …
advancement of many emerging biomedical technologies including the development of …
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review
C Aparicio, C Acebal, M González-Vallinas - Experimental Hematology & …, 2023 - Springer
Chimeric antigen receptor (CAR)-T cell therapy is one of the most promising advances in
cancer treatment. It is based on genetically modified T cells to express a CAR, which …
cancer treatment. It is based on genetically modified T cells to express a CAR, which …
Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies
Allogeneic cellular immunotherapies hold promise for broad clinical implementation but face
limitations due to potential rejection of donor cells by the host immune system. Silencing of …
limitations due to potential rejection of donor cells by the host immune system. Silencing of …
Guanidyl-Rich Poly (β amino ester) s for Universal Functional Cytosolic protein delivery and clustered regularly interspaced short palindromic repeats (CRISPR) Cas9 …
X Wang, Y Li, X Wang, DM Sandoval, Z He, IL Sáez… - ACS …, 2023 - ACS Publications
Protein therapeutics are highly promising for complex disease treatment. However, the lack
of ideal delivery vectors impedes their clinical use, especially the carriers for in vivo delivery …
of ideal delivery vectors impedes their clinical use, especially the carriers for in vivo delivery …
BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
HLA‐G is considered as an immune checkpoint protein and a tumor‐associated antigen. In
the previous work, it is reported that CAR‐NK targeting of HLA‐G can be used to treat certain …
the previous work, it is reported that CAR‐NK targeting of HLA‐G can be used to treat certain …
Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells
Background Multiple genetic modifications may be required to develop potent off-the-shelf
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …
Genetically engineered hypoimmunogenic cell therapy
Immune rejection is an important obstacle to the use of allogeneic 'off-the-shelf'cells for
transplantation into immunocompetent patients. Genetic modification has emerged as a …
transplantation into immunocompetent patients. Genetic modification has emerged as a …
Four challenges to CAR T cells breaking the glass ceiling
Cell‐based therapies using chimeric antigen receptor T cells (CAR T) have had dramatic
efficacy in the clinic and can even mediate curative responses in patients with hematologic …
efficacy in the clinic and can even mediate curative responses in patients with hematologic …